Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Theophylline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 9/20 | 0.93 |
| ▸ | PDE4B known ✓ | Q07343 | 9/20 | 0.93 |
| ▸ | PDE4C known ✓ | Q08493 | 9/20 | 0.93 |
| ▸ | PDE4D known ✓ | Q08499 | 9/20 | 0.93 |
| ▸ | ADORA2A known ✓ | P29274 | 8/20 | 0.93 |
| ▸ | ADORA2B known ✓ | P29275 | 8/20 | 0.93 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.93 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.93 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.60 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.60 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.96 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.93 |
| ▸ | ALPL | P05186 | 1/20 | 0.93 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | CFTR | P13569 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theophylline Anhydrous SCHEMBL27932629 | 1.00 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL25398274 | 0.98 | ATAD2 (1.00) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL4915 | 0.98 | ATAD2 (1.00) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL3051675 | 0.98 | ATAD2 (1.00) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL11459710 | 0.96 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL21753826 | 0.96 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL7721325 | 0.96 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL8375983 | 0.96 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL1274777 | 0.96 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL5454758 | 0.96 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2026-03-17 | — | — | US | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220064138-A1 | MACROLIDE BREFELDIN A ESTER DERIVATIVES AND USE THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2022-03-03 | — | — | US | disclosed |
| CN-107573338-B | Fe (III) magnetic compound based on different alkaloids and synthetic method thereof | 四川大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-107592807-A | Cyclic olefin polymer container with damage resistant and anlistatig coating | SIO2医药产品公司 | 2018-01-16 | — | — | CN | disclosed |
| CN-107573338-A | A kind of Fe (III) magnetic compounds and its synthetic method based on different alkaloids | 四川大学 | 2018-01-12 | — | — | CN | disclosed |
| EP-1915156-B1 | USE OF PSYCHOMOTOR STIMULANTS AND COMPOSITIONS CONTAINING THEM IN A METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION | PROVIMI HOLDING B V (NL) | 2012-07-11 | — | — | EP | disclosed |
| US-20110142957-A1 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION | CARGILL THE NETHERLANDS HOLDING B.V. (NL) | 2011-06-16 | — | — | US | disclosed |
| US-7893070-B2 | Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion | PROVIMI HOLDING B.V. (NL) | 2011-02-22 | — | — | US | disclosed |
| EP-1469834-A4 | MULTI-STAGE ORAL DRUG CONTROLLED-RELEASE SYSTEM | PACIFIC CORP (KR) | 2006-07-05 | — | — | EP | disclosed |
| CN-1625390-A | Multi-stage oral drug controlled-release system | PACIFIC CORP (KR) | 2005-06-08 | — | — | CN | disclosed |
| EP-1469834-A1 | MULTI-STAGE ORAL DRUG CONTROLLED-RELEASE SYSTEM | PACIFIC CORPORATION (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-20030180362-A1 | Multi-stage oral drug controlled-release system | PACIFIC CORPORATION (KR) | 2003-09-25 | — | — | US | disclosed |
| WO-2003063834-A1 | MULTI-STAGE ORAL DRUG CONTROLLED-RELEASE SYSTEM | PACIFIC CORPORATION (KR) | 2003-08-07 | — | — | WO | disclosed |
| US-5019723-A | Electret membrane | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 1991-05-28 | — | — | US | disclosed |
| US-4871352-A | Self-regulated therapeutic agent delivery system and method | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 1989-10-03 | — | — | US | disclosed |
| WO-1989005167-A1 | SELF-REGULATED THERAPEUTIC AGENT DELIVERY SYSTEM AND METHOD | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 1989-06-15 | — | — | WO | disclosed |
| US-4822339-A | Therapeutic agent delivery system and method | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0108218-A2 | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility | VEREX LABORATORIES, INC. (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064138-A1 | MACROLIDE BREFELDIN A ESTER DERIVATIVES AND USE THEREOF | MAN2B1, MAN1B1, FUCA1 | PDE4A 3056/4885PDE4B 3253/4885PDE4C 3511/4885 |
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | BCL6, BCL6B, BCL3 | PDE4A 4710/4885PDE4B 4556/4885PDE4C 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.